Zoetis Inc. $ZTS Shares Bought by Vantage Wealth

Vantage Wealth lifted its position in Zoetis Inc. (NYSE:ZTS) by 20.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 130,555 shares of the company’s stock after buying an additional 22,085 shares during the quarter. Zoetis makes up approximately 3.6% of Vantage Wealth’s investment portfolio, making the stock its 22nd largest position. Vantage Wealth’s holdings in Zoetis were worth $16,426,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in Zoetis by 1.0% during the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock valued at $6,190,326,000 after buying an additional 419,777 shares in the last quarter. Nordea Investment Management AB raised its position in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares in the last quarter. Brown Advisory Inc. lifted its holdings in Zoetis by 5.7% in the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock valued at $726,629,000 after acquiring an additional 250,829 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Zoetis by 14.6% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock valued at $631,046,000 after acquiring an additional 550,859 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of Zoetis by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock valued at $620,595,000 after purchasing an additional 496,320 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. BTIG Research reiterated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Morgan Stanley set a $160.00 price target on Zoetis in a report on Thursday, December 18th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Finally, Piper Sandler reissued a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Stock Performance

Shares of ZTS opened at $113.48 on Monday. The company has a 50-day moving average of $123.39 and a two-hundred day moving average of $129.03. The stock has a market cap of $47.90 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 1.73 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a one year low of $113.29 and a one year high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.